Yıl: 2023 Cilt: 53 Sayı: 6 Sayfa Aralığı: 1722 - 1731 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5741 İndeks Tarihi: 17-01-2024

Management and prognosis of patients with cancer of unknown primary: 20 years of experience

Öz:
Background/aim: Cancer of unknown primary (CUP) is a difficult clinical entity to manage. The aim of the study was to investigate the sociodemographic and pathological characteristics, treatment options, and factors affecting overall survival (OS) in CUP patients whose primary tumor was not detected during follow-up. Materials and methods: A total of 243 CUP patients whose primary tumors could not be detected during follow-up were included in the study. Their demographic characteristics, survival outcomes, and prognostic factors were investigated. Results: Of the 243 patients included in this study, 61.7% were male and 38.3% were female, and the median age was 61 (range: 19–90) years. The most common histological type was adenocarcinoma (79%). The median follow-up time of the patients was 30.3 months (95% CI: 11.4–49.3), the median OS time was 9.1 months (95% CI: 7.2–11.0), and 72.4% of the patients received at least 1 line of chemotherapy (CT). The difference in survival between the patients who did and did not receive CT was statistically significant (median OS: 10.1 vs. 4.2 months, p = 0.003). According to the multivariate analysis, the presence of cholestasis (HR: 0.48, 95% CI: 0.29–0.79, p = 0.004), lung metastasis (HR: 0.69, 95% CI: 0.51–0.95, p = 0.001), second-line chemotherapy (HR: 1.69, 95% CI: 1.14–2.49, p < 0.001), and Eastern Cooperative Oncology Group (ECOG) performance status (HR: 0.20, 95% CI: 0.10–0.40, p < 0.001) were independent prognostic factors influencing OS. Conclusion: CUP patients who receive multiple lines of chemotherapy tend to have longer survival. This is the first study to report cholestasis as a prognostic factor in CUP patients. In addition, the presence of lung metastases, not receiving second-line chemotherapy, and ECOG performance status (≥2) were found to be independent poor prognostic factors.
Anahtar Kelime: Cancer of unknown primary cholestasis lung metastasis chemotherapy prognosis

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Critical Reviews in Oncology/Hematology 2009; 69 (3): 271- 278. https://doi.org/10.1016/j.critrevonc.2008.09.005
  • 2. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta- analysis. European Radiology 2009; 19 (3): 731-744. https://doi. org/10.1007/s00330-008-1194-4
  • 3. Van de Wouw A, Janssen-Heijnen M, Coebergh J, Hillen H. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. European Journal of Cancer 2002; 38 (3): 409-413. https://doi.org/10.1016/S0959-8049(01)00378-1
  • 4. Varadhachary GR, Raber MN. Cancer of unknown primary site. New England Journal of Medicine 2014; 371 (8): 757-765. https://doi.org/10.1056/NEJMra1303917
  • 5. Hemminki K, Riihimäki M, Sundquist K, Hemminki A. Site specific survival rates for cancer of unknown primary according to location of metastases. International Journal of Cancer 2013; 133 (1): 182-189. https://doi.org/10.1002/ijc.27988
  • 6. Vikeså J, Møller AKH, Kaczkowski B, Borup R, Winther O et al. Cancers of unknown primary origin (CUP) are characterized by chromosomal instability (CIN) compared to metastasis of know origin. BMC Cancer 2015; 15 (1): 1-14. https://doi. org/10.1186/s12885-015-1128-x
  • 7. Pavlidis N, Khaled H, Gaafar R. A mini review on cancer of unknown primary site: a clinical puzzle for the oncologists. Journal of Advanced Research 2015; 6 (3): 375-382. https://doi. org/10.1016/j.jare.2014.11.007
  • 8. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL et al. Cancer treatment and survivorship statistics, 2016. CA: A Cancer Journal for Clinicians 2016; 66 (4): 271-289. https://doi. org/10.3322/caac.21349
  • 9. Varadhachary GR, Raber MN. Carcinoma of unknown primary site. New England Journal of Medicine 2014; 371 (21): 2040. https://doi.org/10.1056/nejmc1411384
  • 10. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. The Lancet 2012; 379 (9824): 1428-1435. https://doi. org/10.1016/S0140-6736(11)61178-1
  • 11. Hussien NM, Elsayed Z, Ibrahim DR, Eltabakh FM. Predictors of survival of patients with cancer of unknown primary site: a retrospective study from two institutions in Egypt. Research in Oncology 2022; 18 (2): 69-75. https://doi.org/10.21608/ resoncol.2022.92845.1151
  • 12. Löffler H, Puthenparambil J, Hielscher T, Neben K, Krämer A. Patients with cancer of unknown primary: a retrospective analysis of 223 patients with adenocarcinoma or undifferentiated carcinoma. Deutsches Ärzteblatt International 2014; 111 (27- 28): 481. https://doi.org/10.3238/arztebl.2014.0481
  • 13. Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A et al. Cancer of unknown primary in adolescents and young adults: clinicopathological features, prognostic factors and survival outcomes. PLoS One 2016; 11 (5): e0154985. https://doi. org/10.1371/journal.pone.0154985
  • 14. Algin E, Gumusay O, Yilmaz G, Buyukberber S, Coskun U et al. Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients. Wiener klinische Wochenschrift 2016; 128 (1): 42-47. https:// doi.org/10.1007/s00508-015-0858-8
  • 15. Pavlidis N, Briasoulis E, Hainsworth J, Greco F. Diagnostic and therapeutic management of cancer of an unknown primary. European Journal of Cancer 2003; 39 (14): 1990-2005. https:// doi.org/10.1016/S0959-8049(03)00547-1
  • 16. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. Journal of Clinical Oncology 2008; 26 (27): 4442-4448. https://doi.org/10.1200/ JCO.2007.14.4378
  • 17. Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma X-J, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. The Oncologist 2010; 15 (5): 500-506. https://doi.org/10.1634/theoncologist.2009-0328
  • 18. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon Research Institute. Journal of Clinical Oncology 2013; 31 (2): 217-223. https://doi.org/10.1200/JCO.2012.43.3755
  • 19. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. Journal of Clinical Oncology 1994; 12 (6): 1272-1280. https://doi. org/10.1200/jco.1994.12.6.1272
  • 20. Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F, de la Cruz J. Prognostic factors in cancer of unknown primary site. Tumori Journal 2010; 96 (1): 111-116. https://doi. org/10.1177/030089161009600118
  • 21. Le Chevalier T, Cvitkovic E, Caille P, Harvey J, Contesso G et al. Early metastatic cancer of unknown primary origin at presentation: a clinical study of 302 consecutive autopsied patients. Archives of Internal Medicine 1988; 148 (9): 2035- 2039. https://doi.org/10.1001/archinte.1988.00380090101024
  • 22. Antuña Egocheaga A, López González ML, Lobo Fernández J, Fernández Bustamante J, Moris de la Tassa J et al. Protocolo diagnóstico del cáncer de origen desconocido. Revisión de 157 casos [Diagnostic protocol for unknown primary cancers. Review of 157 cases]. Anales de Medicina Interna 2002; 19 (8): 405-408 (Article in Spanish). PMID: 12244787
  • 23. Pouesse D, Thezenas S, Culine S, Becht C, Senesse P et al. Hepatic metastases from carcinomas of unknown primary site: experience of the Montpellier Cancer Center. Gastroenterologie Clinique et Biologique 2005; 29 (12): 1224-1232. https://doi. org/10.1016/S0399-8320(05)82205-5
  • 24. Shaw P, Adams R, Jordan C, Crosby TDL. A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clinical Oncology 2007; 19 (1): 87-95. https://doi.org/10.1016/j.clon.2006.09.009
  • 25. Chen K-W, Liu C-J, Lu H-J, Tzeng C-H, Liu J-H et al. Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study. BMC Research Notes 2012; 5 (1): 1-10. https:// doi.org/10.1186/1756-0500-5-70
  • 26. Culine S, Lortholary A, Voigt J-J, Bugat R, Théodore C et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study—trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Journal of Clinical Oncology 2003; 21 (18): 3479-3482. https://doi. org/10.1200/JCO.2003.12.104
  • 27. Lee J, Hahn S, Kim D-W, Kim J, Kang S et al. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis. British Journal of Cancer 2013; 108 (1): 39- 48. https://doi.org/10.1038/bjc.2012.516
  • 28. Holtan SG, Steen PD, Foster NR, Erlichman C, Medeiros F et al. Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial. PLoS One 2012; 7 (7): e39285. https://doi.org/10.1371/journal. pone.0039285
  • 29. Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/ irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. The Cancer Journal 2010; 16 (1): 70-75. https://doi.org/10.1097/ PPO.0b013e3181c6aa89
APA BARDAKÇI M, ALGIN E, DÜGEROĞLU B, bal ö, Köş F, UNCU D (2023). Management and prognosis of patients with cancer of unknown primary: 20 years of experience. , 1722 - 1731. 10.55730/1300-0144.5741
Chicago BARDAKÇI MURAT,ALGIN EFNAN,DÜGEROĞLU BÜŞRA,bal öznur,Köş Fahriye Tuğba,UNCU DOGAN Management and prognosis of patients with cancer of unknown primary: 20 years of experience. (2023): 1722 - 1731. 10.55730/1300-0144.5741
MLA BARDAKÇI MURAT,ALGIN EFNAN,DÜGEROĞLU BÜŞRA,bal öznur,Köş Fahriye Tuğba,UNCU DOGAN Management and prognosis of patients with cancer of unknown primary: 20 years of experience. , 2023, ss.1722 - 1731. 10.55730/1300-0144.5741
AMA BARDAKÇI M,ALGIN E,DÜGEROĞLU B,bal ö,Köş F,UNCU D Management and prognosis of patients with cancer of unknown primary: 20 years of experience. . 2023; 1722 - 1731. 10.55730/1300-0144.5741
Vancouver BARDAKÇI M,ALGIN E,DÜGEROĞLU B,bal ö,Köş F,UNCU D Management and prognosis of patients with cancer of unknown primary: 20 years of experience. . 2023; 1722 - 1731. 10.55730/1300-0144.5741
IEEE BARDAKÇI M,ALGIN E,DÜGEROĞLU B,bal ö,Köş F,UNCU D "Management and prognosis of patients with cancer of unknown primary: 20 years of experience." , ss.1722 - 1731, 2023. 10.55730/1300-0144.5741
ISNAD BARDAKÇI, MURAT vd. "Management and prognosis of patients with cancer of unknown primary: 20 years of experience". (2023), 1722-1731. https://doi.org/10.55730/1300-0144.5741
APA BARDAKÇI M, ALGIN E, DÜGEROĞLU B, bal ö, Köş F, UNCU D (2023). Management and prognosis of patients with cancer of unknown primary: 20 years of experience. Turkish Journal of Medical Sciences, 53(6), 1722 - 1731. 10.55730/1300-0144.5741
Chicago BARDAKÇI MURAT,ALGIN EFNAN,DÜGEROĞLU BÜŞRA,bal öznur,Köş Fahriye Tuğba,UNCU DOGAN Management and prognosis of patients with cancer of unknown primary: 20 years of experience. Turkish Journal of Medical Sciences 53, no.6 (2023): 1722 - 1731. 10.55730/1300-0144.5741
MLA BARDAKÇI MURAT,ALGIN EFNAN,DÜGEROĞLU BÜŞRA,bal öznur,Köş Fahriye Tuğba,UNCU DOGAN Management and prognosis of patients with cancer of unknown primary: 20 years of experience. Turkish Journal of Medical Sciences, vol.53, no.6, 2023, ss.1722 - 1731. 10.55730/1300-0144.5741
AMA BARDAKÇI M,ALGIN E,DÜGEROĞLU B,bal ö,Köş F,UNCU D Management and prognosis of patients with cancer of unknown primary: 20 years of experience. Turkish Journal of Medical Sciences. 2023; 53(6): 1722 - 1731. 10.55730/1300-0144.5741
Vancouver BARDAKÇI M,ALGIN E,DÜGEROĞLU B,bal ö,Köş F,UNCU D Management and prognosis of patients with cancer of unknown primary: 20 years of experience. Turkish Journal of Medical Sciences. 2023; 53(6): 1722 - 1731. 10.55730/1300-0144.5741
IEEE BARDAKÇI M,ALGIN E,DÜGEROĞLU B,bal ö,Köş F,UNCU D "Management and prognosis of patients with cancer of unknown primary: 20 years of experience." Turkish Journal of Medical Sciences, 53, ss.1722 - 1731, 2023. 10.55730/1300-0144.5741
ISNAD BARDAKÇI, MURAT vd. "Management and prognosis of patients with cancer of unknown primary: 20 years of experience". Turkish Journal of Medical Sciences 53/6 (2023), 1722-1731. https://doi.org/10.55730/1300-0144.5741